Neurologic complications of plasma cell disorders

Clinical Lymphoma

Volumn 5, Issue 3, 2004, Pages 163-171

  Drappatz, Jan ^a   Batchelor, Tracy ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cord compression; Epidural disease; Hypercalcemia; Hyperviscosity syndrome; Leptomeningeal disease; Peripheral neuropathy

Indexed keywords

4' IODOESORUBICIN; ALKYLATING AGENT; AMYLOID; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GANGLIOSIDE GD 1B; GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; M PROTEIN; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; PROTEIN ANTIBODY; PURINE NUCLEOSIDE DERIVATIVE; RETINOIC ACID; STEROID; STRONTIUM 89; TAMOXIFEN; UNINDEXED DRUG;

AMYLOID NEUROPATHY; AMYLOIDOSIS; ANTIBODY DETECTION; BING NEEL SYNDROME; BLOOD VISCOSITY; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; HUMAN; HYDROCEPHALUS; HYPERCALCEMIA; HYPERVISCOSITY SYNDROME; HYPESTHESIA; KYPHOPLASTY; LABORATORY TEST; MALIGNANT NEOPLASTIC DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEURON DISEASE; MULTIPLE MYELOMA; NERVE BIOPSY; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARAPROTEINEMIA; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PLASMA CELL; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PLASMAPHERESIS; POLYNEUROPATHY; PROTEIN BLOOD LEVEL; RADIOTHERAPY; REVIEW; SPINAL CORD COMPRESSION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 13644250431     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.022     Document Type: Review

References (106)

1. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neuronal IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994; 36:416-424.
2. Vrethem M, Cruz M, Wen-Xin H, et al. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 1993; 114:193-199.
3. Kelly JJ, Kyle RA, O'Brien PC, et al. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31:1480-1483.
4. Yeung KB, Thomas PK, King RHM. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinemia: comparative clinical, immunological and nerve biopsy findings. J Neurol 1991; 238:383-391.
5. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 1991; 30:54-61.
6. Melmed C, Frail D, Duncan I, et al. Peripheral neuropathy with IgM kappa monoclonal immunoglobulin directed against myelin-associated glycoprotein. Neurology 1983; 33:1397-1405.
7. Steck A, Murray N, Meier C, et al. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 1983; 33:19-23.
8. Gabriel JM, Erne B, Miescher GC, et al. Selective loss of myelin associated glycoprotein from myelin correlates with anti-MAG antibody titer in demyelinating paraproteinemic polyneuropathy. Brain 1996; 119:775-787.
9. Ritz MF, Erne B, Ferracin F, et al. Anti MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening. Muscle Nerve 1999; 22:1030-1037.
10. Quarles RH. Glycoproteins of myelin sheaths. J Mol Neurosci 1997; 8:1-12.
11. Vital A. Paraproteinemic neuropathies. Brain Pathol 200 1;11:399-407.
12. Chassande B, Leger JM, Younes-Chennnoufi AB. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and dinical/electrophysiological features in 40 cases. Muscle Nerve 1998; 21:55-62.
13. Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris 2002; 158:979-987.
14. Steck AJ, Kuntzer T. Dysglobulinémies IgM et complications neurologiques. Rev Neurol (Paris) 2002; 158:971-978.
15. Antoine JC, Steck A, Michel D. Neuropathie périphérique avec atteinte motrice prédominante associée à une gammapathie IgM monoclonale anti-MAG. Rev Neurol (Paris) 1993; 149:496-499.
16. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54:615-620.
17. Dabby R, Wiemer LH, Hays Ap, et al. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 2000; 54:1448-1453.
18. Bollensen E, Steck AJ, Schachner M. Reactivity with the peripheral myelin glycoprotein P0 in serum from patients with monoclonal gammopathy and polyneuropathy. Neurology 1988; 38:1266-1270.
19. Ariga T, Kohriyama T, Freddo L, et al. Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy. J Biol Chem 1987; 262:848-853.
20. Eurelings M, Moons KG, Notermans NC, et al. Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 2001; 56:228-233.
21. Nobile-Orazio E, Carpo M. Neuropathy and monoclonal gammopathy. Curr Opin Neurol 2001; 14:615-620.
22. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325:1482-1486.
23. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995; 45:1577-1580.
24. Comi G, Roveri L, Swan A, et al. A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002; 249:1370-1377.
25. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999; 52:1701-1704.
26. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27:611-615.
27. Simmons Z, Albers JW, Bromberg MB, et al. Long term follow up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995; 118:359-368.
28. Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy. Neurology 1992; 42:1157-1163.
29. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24:311-324.
30. Simmons Z, Tivakaran S. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome. Muscle Nerve 1996; 19:1174-1176.
31. Yato M, Ohkoshi N, Sato A, et al. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Eur J Neurol 2000; 7:227-230.
32. Wicklund MP, Kissel JT. Paraproteinemic Neuropathy. Curr Treat Opt Neurol 2001; 3:147-156.
33. Gorson KC, Ropper AH, Weinberg DH, et al. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 2002; 59:766-772
34. Kelly JJ. Polyneuropathies associated with myeloma, POEMS and non-malignant IgG and IgA monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ, eds. Immunological and Infectious Diseases of the Peripheral Nerves. Cambridge, MA: Cambridge University Press, 1998:225-237.
35. Victor M, Banker BQ, Adams RD. The neuropathy of multiple myeloma. J Neurol Neurosurg Psychiatry 1958; 21:73-88.
36. Briemberg HR, Amato AA. Neuromuscular complications of cancer. Neurol Clin 2003; 21:141.
37. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338:1601-1607.
38. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984; 34:712-720
39. Kelly JJ, Kyle RA, Mites JM, et al. Osteosclerotic myeloma and peripheral neuropathy. Neurology 1983; 33:202-210.
40. Kyle RA, Dyck PJ. Osteosclerotic myeloma (POEMS syndrome). In: Dyck P, Thomas P, eds. Peripheral Neuropathies. Philadelphia: WB Saunders, 1992:1288-1293.
41. Authier FJ, Belec I, Levy Y, et al. All-retinoic acid in POEMS syndrome. Therapeutic effect associated with decreased circulating levels of proinflammatory cytokines. Arthritis Rheum 1996; 39:1423-1426.
42. Peggs KS, Paneesha S, Kottaridis PD, et al. Peripheral blood stem cell transplantation for POEMS syndrome. Bone Marrow Transplant 2002; 30:401-404.
43. Sternberg AJ, Davies P, Macmillan C, et al. Strontium-89: a novel treatment for a case of osteosclerotic myeloma associated with life threatening neuropathy. Br J Hematol 2002; 118:821-824.
44. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001; 28:577-582.
45. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide induced neuropathy. Neurology 2002; 59:1872-1875.
46. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinemia. Blood 1994; 83:1452-1459.
47. Nobile-Orazio E, Marmiroli P, et al. Peripheral neuropathy in macroglobulinemia: Incidence and antigen-specificity of M proteins. Neurology 1987; 37:1506-1514.
48. Wooten MD, Jasin HE. Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum 1996; 26:564-74.
49. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001; 248:647-657.
50. Traynor AE, Gertz MA, Kyle RA. Cranial neuropathy associated with primary amyloidosis. Ann Neurol 1991; 29:451-454.
51. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4′-iodo-4′deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002; 9:24-30.
52. Comenzo RL, Gertz M.A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99:4276-4282.
53. Bloch KJ, Franklin E. Plasma cell dyscrasias and cryoglobulins. JAMA 1982; 248:2670-2676.
54. Caniatti LM, Tugnoli V, Eleopra R, et al. Cryoglobulinemic neuropathy related to hepatitis C virus infection. Clinical, laboratory and neurophysiological study. J Peripheral Nerv Syst 1996; 1: 131-138.
55. Garcia-Bragado F, Fernandez JM, Navarro C, et al. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988; 45:1210-1214.
56. Nemni R, Corbo M, Fazio R, et al. Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 1988; 111:541-552.
57. Vallat JM, Lebouter MJ, Loubet A. Cryoglobulinemic neuropathy: ultra-structural study of the nerve capillaries. Acta Neuropathol Suppl (Berl) 1981; 7:252-254.
58. Vital A, Vital C, Ragnaud JM, et al. IgM cryoglobulin deposits in the peripheral nerve. Virchows Arch A Pathol Anat Histopathol 1991; 418:83-85.
59. Akpinar S, Berk O, Karaca L. Paraneoplastic cerebellar degeneration associated with multiple myeloma--3.4 years follow up. J Neurooncol 1990; 9:63-68.
60. Johnson SA, Oscier DG, Leblond V. Waldenstrom's macroglobulinaemia. Blood Rev 2002; 16:175-184.
61. Pruzanski W, Watt JG. Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. Ann Intern Med 1972; 77:853.
62. Preston FE, Cooke KB, Foster ME, et al. Myelomatosis and the hyperviscosity syndrome Br J Haematol 1978; 38:517.
63. Chandy KG, Stockley RA, Leonard RC, et al. Relationship between serum viscosity and intravascular IgA polymer concentration in IgA myeloma. Clin Exp Immunol 1981; 46:653.
64. Logothetis J, Silverstein P, Coe J. Neurologic aspects of Waldenstrom's macroglobulinemia. Arch Neurol 1960; 3:546-573.
65. Blumenthal DT, Glenn MJ. Neurologic manifestations of hematologic disorders. Neurol Clin 2002; 20:265-281.
66. Kwaan HC, Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost 1999; 25:199-208.
67. Syms MJ, Arcila ME, Holtel MR. Waldenstrom's macroglobulinemia and sensorineural hearing loss. Am J Otolaryngol 2001; 22:349-353.
68. Pavy MD, Murphy PL, Virella. G. Paraprotein-induced hyperviscosity: a reversible cause of stroke. Postgrad Med J 1980; 68:109-112.
69. Bernard A, Rousselie F. Macular manifestations of monoclonal dysgammaglobulinemias. Apropos of 3 cases. J Fr Ophtalmol 1986; 9:805-810.
70. Munshi NC, Tricot G, Barlogie B. Plasma Cell Neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles & Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:2465-2509.
71. Bing J, Neel AV. Report of a third case of hyperglobulinemia with affection of the central nervous system on a toxi-infectious basis, and some remarks on the differential diagnosis. Acta Med Scand 1937; 91:409
72. Neau JP, Guilhot F, Dumas P, et al. Central neurologic forms of Waldenstrom's disease. Bing-Neel syndrome. 3 cases. Rev Neurol (Paris) 1991; 147:56-60.
73. Edgar R, Dutcher TF. Histopathology of the Bing-Neel syndrome. Neurology 1961; 11:239-249.
74. Scheithauer BW, Rubinstein LJ, Herman MM. Leukoencephalopathy in Waldenstrom's macroglobulinemia: immunohistochemical and electron microscopic observations. J Neuropathol Exp Neurol 1984; 43:408-425.
75. Welch D, Whetsell WO Jr, Weil R. Pathologic quiz case. A man with long-standing monoclonal gammopathy and new onset of confusion. Central nervous system involvement by Waldenstrom macroglobulinemia-Bing-Neel syndrome. Arch Pathol Lab Med 2002; 126:1243-1244.
76. Delgado J, Canales MA, Garcia B, et al. Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: case report and review of the literature. Am J Hematol 2002; 69:127-131.
77. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117:103-108.
78. Dyck PJ, Low PA, Windebank AJ, et al. Meningeal involvement in Bence Jones multiple myeloma. Cancer 1991; 67:1900-1902.
79. Sham RL, Phatak PD, Kouides PA, et al. Hematologic neoplasia and the central nervous system. Am J Hematol 1999; 62:234-238.
80. Patriarca F, Zaja F, Silvestri F, et al. Meningeal and cerebral involvement in multiple myeloma patients. Ann Hematol 2001; 80:758-762.
81. Leifer D, Grabowski T, Simonian N, et al. Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings. Cancer 1992; 70:1899-1904.
82. Woodruff RK, Ireton HJ. Multiple cranial nerve palsies as the presenting feature of meningeal myelomatosis. Cancer 1982; 49:1710-1712.
83. Pizzuti P, Pertuiset E, Chaumonnot F, et al. Neuromeningeal sites of multiple myeloma: 3 cases and review of the literature. Rev Med Interne 1997; 18:646-651.
84. Shone GR. Facial palsy due to myeloma of the temporal bone. J Laryngol Otol 1985; 99:907-908.
85. Knapp AJ, Gartner S, Henkind P. Multiple myeloma and its ocular manifestations. Surg Ophthalmol 1987; 31:343-351.
86. Bellan LD, Cox TA, Gascoyne RD. Parasellar syndrome caused by plasma cell dyscrasia. Can J Ophthalmol 1989; 24:331-334.
87. Hogan MC, Lee A, Solberg LA, et al. Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. Am J Hematol 2002; 70:55-59.
88. Clarke E. Cranial and intracranial myelomas. Brain 1954; 77:61-81.
89. Witt C, Borges AC, Klein K, et al. Radiographic manifestations of multiple myeloma in the mandible: a retrospective study of 77 patients. J Oral Maxillofac Surg 1997; 55:450-453.
90. Dennis M, Chu P. A case of meningeal myeloma presenting as obstructive hydrocephalus - a therapeutic challenge. Leuk Lymphoma 2000; 40:219-220.
91. Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999; 62:228-233.
92. Colak A, Cataltepe O, Erbengi A. Spinal cord compression caused by plamacytomas: a retrospective series of 14 cases. Neurosurg Rev 1989; 12:305-308.
93. Speiss JL, Adelstein DJ, Hines JD. Multiple myeloma presenting with spinal cord compression. Oncology 1988; 45:88-92.
94. Schiff D. Spinal cord compression. Neurol Clin 2003; 21:67.
95. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med 1992; 327:614-649.
96. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995; 32:959-967.
97. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978; 3:40-51.
98. Dudeney S, Lieberman IH, Reinhardt MK, et al. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002; 20:2382-2387.
99. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98:21-30.
100. Berenson JR. Bisphosphonates in multiple myeloma. Cancer 1997; 80(8 suppl):1661-1667.
101. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21-33.
102. Mundy GR. Myeloma bone disease. Eur J Cancer 1998; 34:246-251.
103. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003; 102:311-319.
104. Riggs JE. Neurologic manifestations of electrolyte disturbances. Neurol Clin 2002; 20:227-239.
105. Shy ME, Rowland LP, Smith T, et al. Motor neuron disease and plasma cell dyscrasia. Neurology 1986; 36:1429-1436.
106. Gordon PH, Rowland LP, Younger DS, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 1997; 48:1671-1678.